Lewis Sanders
Sanders Capital
Lewis Sanders Abbott Laboratories stake
total: 132
Sanders Capital ABT trades
- Total transactions:
- 11
- New positions:
- 1
- Added:
- 2
- Reduced:
- 8
- Held since:
- 2023 Q4
- Held for:
- 11 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Lewis Sanders holds 1,050,405 Abbott Laboratories (ABT) shares with a market value of roughly $95.31M accounting for 0.10% of the overall portfolio. To date, the estimated cost basis is nearly $110.07 for "buy" trades and estimated average "sell" price is $104.37. Sanders Capital first purchased ABT in 2023 Q4, initially acquiring about 1.19M shares. Since the initial investment in Abbott Laboratories (ABT), Sanders Capital has made 10 more transactions.
When did Lewis Sanders buy Abbott Laboratories (ABT)?
Lewis Sanders first invested in Abbott Laboratories (ABT) in 2023 Q4 at the reported quarter-end price of $110.07 per share.
What's the cost basis of Sanders Capital's ABT stake?
The estimated cost basis for Abbott Laboratories (ABT) stake is around $110.07 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $110.07
- Weighted AVG sell price:
- $104.37
Lewis Sanders's historical trades in Abbott Laboratories
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.10%
|
1,050,405
|
$90.74
|
$95,313,750
|
-6.31% (-70,800)
|
-0.01%
|
|
2026 Q1
|
0.14%
|
1,121,205
|
$102.67
|
$115,114,117
|
-2.64% (-30,380)
|
-0%
|
|
2025 Q4
|
0.17%
|
1,151,585
|
$125.29
|
$144,282,085
|
-2.92% (-34,660)
|
-0.01%
|
|
2025 Q3
|
0.20%
|
1,186,245
|
$133.94
|
$158,885,655
|
-0.12% (-1,450)
|
-0%
|
|
2025 Q2
|
0.22%
|
1,187,695
|
$136.01
|
$161,538,397
|
+0.10% (+1,160)
|
+0%
|
|
2025 Q1
|
0.24%
|
1,186,535
|
$132.65
|
$157,393,868
|
-0.61% (-7,276)
|
-0%
|
|
2024 Q4
|
0.20%
|
1,193,811
|
$113.11
|
$135,031,962
|
-0.11% (-1,340)
|
-0%
|
|
2024 Q3
|
0.20%
|
1,195,151
|
$114.01
|
$136,259,166
|
-0.26% (-3,097)
|
-0%
|
|
2024 Q2
|
0.19%
|
1,198,248
|
$103.91
|
$124,509,950
|
+0.44% (+5,290)
|
+0%
|
|
2024 Q1
|
0.23%
|
1,192,958
|
$113.66
|
$135,591,606
|
-0.01% (-120)
|
-0%
|
|
2023 Q4
|
0.24%
|
$110.07
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.